ClinicalTrials.gg
CompletedNCT00236379Updated May 17, 2011

A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder

A Phase 4 interventional study of Olanzapine and Risperidone in Schizophrenia and Diabetes Mellitus, sponsored by Janssen, LP. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-05-17.

Sponsored by Janssen, LP (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
64th of 94
59 · median 114
Phase 4
46 of 97
1 open now
Registered
29th of 97
by date

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 64th largest by enrollment of the 94 interventional ones that give a count, is one of 46 in phase 4, and was the 29th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.

Read the detailed description

The newer antipsychotic medications risperidone and olanzapine effectively treat schizophrenia and related disorders, and they may cause fewer side effects than the older antipsychotic drugs do. However, some of the newer antipsychotic medications could have a negative effect on the regulation of blood glucose (sugar) in the body. This negative effect could make the patient gain weight and even develop diabetes mellitus. This randomized, double-blind study will assess and compare how risperidone and olanzapine affect the regulation of glucose in the body in patients with schizophrenia and schizoaffective disorder. Patients will be randomly assigned to receive risperidone (target oral dose of 6 milligrams per day) or olanzapine (target oral dose of 20 milligrams per day) for 6 months. Repeat laboratory measurements will be performed and questions will be asked of the patients to evaluate the safety and effectiveness of the drugs. The primary laboratory test used to assess the patient's regulation of blood glucose will be the Disposition Index derived from the Frequently Sampled Intravenous Glucose Tolerance Test. Risperidone 2 milligram oven-encapsulated tablets taken orally once a day for 6 months; olanzapine 5 milligram tablets taken orally once a day for 6 months

03

Conditions studied

  • Schizophrenia
  • Diabetes Mellitus

Keywords

  • schizophrenia
  • blood glucose
  • glucose metabolism
  • diabetes mellitus
  • risperidone
  • olanzapine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of schizophrenia or related disorder
  • stable with respect to disease symptoms and other medical conditions
  • would benefit from this type of antipsychotic drug
  • if female, using .

Exclusion criteria

Exclusion Criteria:

  • Patients who are delirious, bipolar, severely mentally retarded, or suicidal
  • psychiatric diagnosis of disease unrelated to schizophrenia
  • presence of stroke, brain tumor, Parkinson's Disease, or diseases that affect blood glucose control
  • history of diabetes
  • long or recent history of taking risperidone, olanzapine, quetiapine, clozapine, or drugs
  • recent history of unstable thyroid function
  • if female, not using
  • abusing drugs or alcohol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
59 participants (actual)

Study arms

  • Experimental
    001

    Risperidone Target oral dose of 6 milligrams per day for for 6 months

    Drug: Risperidone

  • Experimental
    002

    Olanzapine Target oral dose of 20 milligrams per day for 6 months

    Drug: Olanzapine

Interventions

  • Target oral dose of 20 milligrams per day for 6 months

  • Target oral dose of 6 milligrams per day for for 6 months

06

What researchers measure

Primary outcomes

  1. Change in the Disposition Index derived from the Frequently Sampled Intravenous Glucose Tolerance Test (which shows how the body regulates glucose)

    Time frame: Up to 6 months

Secondary outcomes

  1. Changes in measurements of metabolism and glucose regulation; changes in results of tests and questionnaires evaluating the effectiveness and safety (including laboratory tests and anthropomatic measurements) of medications used to treat schizophrenia

    Time frame: Up to 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00236379
Lead sponsor
Janssen, LP
First posted
Oct 12, 2005
Completion
Aug 2003
Last update
May 17, 2011

Study contacts

Janssen, LP Clinical Trial
study director · Janssen, LP
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olanzapine · Risperidone

Start the discussion